National Institute for Health and Care Research

By NIHRScience

National Institute for Health and Care Research episodes

June 23, 2021 AGILE initiative: Influencing future treatment development
View the accessible transcript of this podcast

Thomas Jaki, Professor in Statistics at Lancaster University talks to Professor Allan Gaw about the AGILE platform trial which specifically looks at novel (new) treatments for COVID19, as opposed to repurposed treatments.

Professor Jaki describes how the efficient platform approach enables investigating treatment benefit (efficacy) and dosage in parallel and explains why AGILE is a stellar example of cross-sector collaboration. He also looks to the future: "we're hoping that the learnings from AGILE is going to lead to a much better, much faster, setting up of studies and a much more efficient way to undertake treatment development in the future."

This podcast is part of our 'Perspectives from the Pandemic' series looking at the delivery of Complex and Innovative Design (CID) trials in the COVID-19 pandemic. You can access the full series of #ComplexInnovativeDesign trial podcasts on our website: www.nihr.ac.uk/documents/delivering-complex-and-innovative-trials-podcast-collection/29517

To find out more about how the NIHR supports complex and innovative design trials, visit: www.nihr.ac.uk/innovative-trials
9 min
June 09, 2021 Lessons learned from a flagship platform trial: FOCUS4
View the accessible transcript of this podcast

Professor Tim Maughan talks to Professor Allan Gaw about lessons learnt from delivering the world-renowned, molecularly stratified FOCUS4 platform trial He explains how this flagship trial was designed to respond to a need for a systematic approach to quickly understand which emerging, innovative cancer treatments worked against which cancers. He also describes why one of the biggest challenges was engaging life science companies. Finally he points to how this, and other ground-breaking cancer platform trials, have paved the way for COVID19 platform trials like RECOVERY which have saved thousands of lives around the globe.

This podcast is part of our 'Perspectives from the Pandemic' series looking at the delivery of Complex and Innovative Design (CID) trials in the COVID-19 pandemic. You can access the full series of #ComplexInnovativeDesign trial podcasts on our website: www.nihr.ac.uk/documents/delivering-complex-and-innovative-trials-podcast-collection/29517

To find out more about how the NIHR supports complex and innovative design trials visit: www.nihr.ac.uk/innovative-trials
16 min
April 21, 2021 Octopus: Growing the armoury of MS treatments
View the accessible transcript of this podcast

Dr Emma Gray talks to Professor Allan Gaw about the clinical trial platform for Multiple Sclerosis studies, known as 'Octopus'.

She explains how the Multi-Arm, Multi-Stage platform trial design will help to speed up the development of novel or repurposed treatments for MS that can slow neurodegeneration and/or protect nerves from further damamge (neuroprotective). She also explains how the research team looked to the STAMPEDE prostate cancer trial for inspiration, and how cross-sector collaboration with the NIHR, the life sciences industry and chariites was crucial.

This podcast is part of our 'Persectives from the Pandemic' series looking at the delivery of Complex and Innovative Design (CID) trials in the COVID-19 pandemic. You can access the full series of #ComplexInnovativeDesign trial podcasts on our website: www.nihr.ac.uk/documents/delivering-complex-and-innovative-trials-podcast-collection/29517

To find out more about how the NIHR supports complex and innovative design trials, visit: www.nihr.ac.uk/innovative-trials
17 min
March 24, 2021 Dr Hugh Davies How the C-19 pandemic & clinical experience can be a new preface to clinical research
Dr Hugh Davies chair of the Oxford research ethics committee and was formerly a research ethics advisor to the health research authority. Dr. Davies trained in medicine and was a consultant paediatrician for many years.
Transcript: https://docs.google.com/document/d/1JJR0JF_1jPKOoxN45M-xZtD8obbEWd9S3ezHKR5f-K0/edit?usp=sharing
12 min
March 24, 2021 Why the pandemic provides us with a preface to future research
View the accessible transcript of this podcast

Dr Hugh Davies talks to Professor Allan Gaw about how research ethics approval services adpated during the pandemic to rapidly approve urgent public health research applications.

As well as pointing to practical shifts, such as the switch from fewer face to face meetings to more frequent Zoom meetings, Dr Davies also describes a change of mindset. He describes how ethics panels had to revisit how they assess the benefit and risk balance when considering the burden of delivering research in a pandemic situation, against the desperate need to generate clinical evidence for what treatments work, and don't work.

This podcast is part of our 'Persectives from the Pandemic' series looking at the delivery of Complex and Innovative Design (CID) trials in the COVID-19 pandemic. You can access the full series of #ComplexInnovativeDesign trial podcasts on our website: www.nihr.ac.uk/documents/delivering-complex-and-innovative-trials-podcast-collection/29517

To find out more about how the NIHR supports complex and innovative design trials, visit:www.nihr.ac.uk/innovative-trials
12 min
March 17, 2021 Professor Matt Sydes - The importance of communicating trial results to the study participants.
Matt Sydes Professor of Clinical Trials and Methodology at the MRC Clinical Trials Unit at University College London.
The importance of communicating trial results to the study participants.
Transcript:https://docs.google.com/document/d/1_tCdh1o9gWFsu5yXeTyXf8JDozGWF4qNrVTspeWNoFA/edit?usp=sharing
13 min
March 17, 2021 The complexities of communicating results to #ComplexInnovativeDesign trial participants
View the accessible transcript of this podcast

Professor Matt Sydes talks to Professor Allan Gaw about some of the challenges that researchers need to consider when communicating research findings to participants who have taken part in complex design trials such as a MAMS trial - multi-arm, multi-stage trial.

If a multi-arm platform trial answers more than one research question, should ALL participants hear about ALL the findings? Or just the arm they participated in? Matt draws on his experiences of the world-renowned STAMPEDE trial to offer some guidance.

This podcast is part of our 'Persectives from the Pandemic' series looking at the delivery of Complex and Innovative Design (CID) trials in the COVID-19 pandemic. You can access the full series of #ComplexInnovativeDesign trial podcasts on our website: www.nihr.ac.uk/documents/delivering-complex-and-innovative-trials-podcast-collection/29517

To find out more about how the NIHR supports complex and innovative design trials, visit: www.nihr.ac.uk/innovative-trials

You can listen to all our full collection of #ComplexInnovativeDesign trial podcasts on our website
13 min
March 10, 2021 Professor Sir Munir Pirmohamed The NHS, UK's not so secret weapon in delivering Covid-19 research
Professor Sir Munir Pirmohamed - The NHS, the UK’s not so secret weapon in delivering Covid-19 research.
COVID-19 - the importance of embedding research and the clinical care interface as a whole, working seamlessly together, to improve future outcomes for patients.
Transcript:https://docs.google.com/document/d/1tvGNL5rWd7t3NVbtWy1z8HJPzVPfZR9db-NgwmRCXf8/edit?usp=sharing
14 min
March 10, 2021 NHS: the UK's not so secret weapon against COVID-19
View the accessible transcript of this podcast

Professor Sir Munir Pirmohamed talks to Professor Allan Gaw about how the UK was able to rapidly adapt to the quest to find new treatments for COVID-19.

He points to key ingredients such as the NIHR research workforce, fast-tracked funding decisions, reduced bureaucracy, collaborative research culture - all of which contributed to the UK's success. Importantly, he also recognises that none of this could have been possible without the infrastructure and data systems provided by the NHS and he explains how the UK's integrated health research system was critical to the delivery of the hugely successful COVID-19 platform trials.

This podcast is part of our 'Persectives from the Pandemic' series looking at the delivery of Complex and Innovative Design (CID) trials in the COVID-19 pandemic. You can access the full series of #ComplexInnovativeDesign trial podcasts on our website: www.nihr.ac.uk/documents/delivering-complex-and-innovative-trials-podcast-collection/29517

To find out more about how the NIHR supports complex and innovative design trials, visit: www.nihr.ac.uk/innovative-trials
14 min
March 03, 2021 Professor Thomas Jaki - The AGILE initiative and the advantages and challenges of Platform Trials.
Professor Thomas Jaki - Professor of Statistics at Lancaster University and Programme Leader at the MRC Biostatistics Unit at the University of Cambridge
The AGILE initiative and the advantages and challenges of Platform Trials.
Transcript: https://docs.google.com/document/d/1ad6R8yTfRsdna7Wk442ybKHwPB4h5oZF3WzUqqEMubw/edit?usp=sharing
9 min

About National Institute for Health and Care Research

From the publisher's feed

The National Institute for Health and Care Research (NIHR): funding, enabling and delivering world-class health and care research that transforms people's lives. Visit our website: www.nihr.ac.uk